Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00902460 · ClinicalTrials.gov registry record · Phase 1
CP-690,550 and Midazolam Drug-Drug Interaction Study
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00902460 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 25 participants.
The verdict
NCT00902460, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
CP-690,550 and midazolam are metabolized by similar enzymes in the liver. This study is designed to assess whether co-administration of CP-690,500 and midazolam will effect the metabolism of midazolam in healthy volunteers.
Interventions
- DRUG midazolam; CP-690,550 + midazolam
- DRUG CP-690,550 + midazolam; midazolam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2009-06 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00902460
The ClinicalTrials.gov registry entry for NCT00902460 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which midazolam; CP-690,550 + midazolam is the first listed.
NCT00902460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00902460 about?
NCT00902460 is a clinical study titled "CP-690,550 and Midazolam Drug-Drug Interaction Study". CP-690,550 and midazolam are metabolized by similar enzymes in the liver. This study is designed to assess whether co-administration of CP-690,500 and midazolam will effect the metabolism of midazolam in healthy volunteers.
What is the current status of trial NCT00902460?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2009-06. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00902460?
The interventions under investigation include: midazolam; CP-690,550 + midazolam (DRUG), CP-690,550 + midazolam; midazolam (DRUG).
Who is sponsoring clinical trial NCT00902460?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.